Mara Aspinall

Jun 22, 2017

OraSure Technologies has appointed Mara Aspinall to its board of directors. Aspinall currently serves as the president and CEO of Health Catalysts. She also serves as the executive chairman of GenePeeks. Prior to these positions, Aspinall served as president, CEO and global head of Roche Tissue Diagnostics. She also founded and served as CEO and director of On-Q-ity, served as president of Genzyme Genetics, served as president of the Genzyme Pharmaceuticals.

More Like This

May 22, 2018

Steve Ayer

TriCore Reference Laboratories announced the appointment of Steve Ayer as chief information officer as well as CEO of the company's The Rhodes Group, TriCore's healthcare software and analytics subsidiary. Ayer has served as TriCore's interim CIO for the past several months.

May 18, 2018

William Denman

William Denman, chief medical officer and founding member of Premaitha Health, has stepped down as director and consultant to the company.

May 17, 2018

Helen Torley

Quest Diagnostics announced that Helen Torley was elected to serve as a director during the company's 2018 annual meeting of stockholders, expanding the board of directors to 10 members. Torley had been president, CEO and director of Halozyme Therapeutics since 2014. She previously served as executive vice president and chief commercial officer for Onyx Pharmaceuticals, as vice president and general manager for Amgen's US bone health and nephrology business, and in various senior management positions at Bristol-Myers Sqibb and Sandoz/Novartis. She was formerly in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glascow, Scotland.

May 16, 2018

John Potthoff

John Potthoff has been appointed to the board of Chembio Diagnostics. He is currently CEO of Elligo Health Research. Prior to that, he was CEO of Theorem Clinical Research. Potthoff also is on the boards of Advarra and SynteractHCR. 

May 15, 2018

Rolland Carlson, Tanja Dowe, Katleen Verleysen

Immunexpress has appointed Rolland Carlson, Tanja Dowe, and Katleen Verleysen to its board. The company also noted that Bea Arnold has stepped down from the board after a three-year tenure.

Carlson was appointed CEO of Immunexpress last month, and previously served as president and CEO at both WaferGen Biosystems and Asuragen. Dowe currently serves as CEO of Debiopharm Innovation Fund, the strategic corporate fund of Debiopharm Group. Verleysen is CEO of CellSeeQ. Prior to that, she held various positions at Pronota, including CEO and chief operating officer.

May 14, 2018

Peter Knight

Peter Knight has joined Bioaffinity Technologies's board. Knight founded investment firm Generation Investment Mangement with Al Gore and David Blood. Prior to that, he was a managing director at Met West Financial. He was also general counsel at Medicis Pharmaceutical, and he started his career at the Antitrust Division of the US Department of Justice. He later was chief of staff to Al Gore. 

May 11, 2018

Bruce Walton

Aurora Diagnostics named Bruce Walton its president. He will also continue as Aurora's COO, a position he has had since 2015 when he was also named the company's executive vice president. Walton joined Aurora in 2009.

May 09, 2018

Gail Miller

Gail Miller has been appointed the chair of Intermountain Healthcare's board, succeeding Scott Anderson, who stepped down after completing his six-year term as the chair. He remains on the board as chair emeritus.

Miller joined Intermoutain's board in 2013 and serves on several committees, including the executive committee and the community relations committee. She is the owner of the Larry H. Miller Group of Companies and chair of its board. 

May 08, 2018

Stephanie Bywater

Stephanie Bywater has been appointed chief compliance officer at NeoGenomics. Her appointment became effective May 1, and she replaces Steven Jones, who will remain an executive vice president and board member at the company. Jones and NeoGenomics reached an agreement in November 2016 where he would reduce his time commitment to the firm, effective May 1 2018.

Bywater has been compliance officer at NeoGenomics since May 2017 when she joined the firm. She was previously global compliance operations and Americas compliance officer at Varian Medical Systems. Before that, she was the compliance and prvacy officer for Myriad Genetics. 

May 08, 2018

Michael Stocum

Michael Stocum has stepped down as CEO of Inivata "to pursue other interests," according to the company. Inivata said it has initiated a search for a new CEO.

May 08, 2018

Laurie Goodman

Laurie Goodman has been promoted to interim CEO of ClearLight Diagnostics, replacing Sarah McCurdy, who resigned as CEO. Goodman will also continue to serve as the company's CSO.  

May 04, 2018

Roberto Cuca

OraSure Technologies said that Roberto Cuca has been appointed its CFO, effective June 8. He replaces Ronald Spair, who is retiring from OraSure. Cuca will initially be a senior advisor to the company until June 8. He has been senior vice president and CFO at Trevena since 2013. Prior to that, he held various leadership positions in the finance organization of Endo Health Solutions. 

May 04, 2018

Charles Bodner

Becton Dickinson has elected Charles Bodner to the role of senior vice president of corporate finance and chief accounting officer. Effective July 1, 2018, Bodner will replace John Gallagher, who will transition to another senior role at BD. Bodner has been BD's senior vice president and CFO of the firm's medical segment since 2013, and CFO of the international business segment since 2017.

May 04, 2018

Alberto Mas, Patrick Kaltenbach, Bill Tozzi

Becton Dickinson has announced three executive leadership changes. Alberto Mas will now lead the firm's medical segment; Patrick Kaltenbach will head up life sciences, replacing Mas, effective May 29; and Bill Tozzi will lead the firm's interventional segment on an interim basis.

Mas was head of BD's life sciences business for two years, and previously served as president of three of the firm's other major business units. Kaltenbach previously served as senior vice president of life sciences and applied markets at Agilent. Tozzi had been serving as the integration leader for the CR Bard transaction since April 2017, and prior to that was the president of the firm's medication delivery solutions division for six years. Tozzi will replace John Groetelaars, who served as the president of the interventional segment since the completion of the Bard transaction and who has decided to leave BD for an executive position at another company.

Mas was head of Life Sciences for two years, and previously served as president of three of the firms other major business units. 

Kaltenbach will replace Mas effective May 29, 2018. He previously served as senior vice president of life sciences and applied markets at Agilent, a position he held since 2014.

Tozzi had been serving as the integration leader for the CR Bard transaction since April 2017, and prior to that was the president of the firm's medication delivery solutions division for six years. Tozzi will replace John Groetelaars, who served as the president of the interventional segment since the completion of the Bard transaction and who has decided to leave BD for an executive position at another company.

May 02, 2018

Charles Brown

LifeLabs, Canada's largest medical laboratory, has announced the appointment of Charles Brown as president and CEO, effective May 1. Brown most recently served as president of The Source, Canada's largest consumer electronics and mobile retailer, owned and operated by Bell Canada. During his tenure with the Bell executive team, he also served as executive vice president of strategic initiatives, where he led the delivery of Bell's telecommunications at the Vancouver 2010 Olympic and Paralympic Winter Games. He has also served as president and CEO of Wave Wireless, and chief information officer of Clearnet.